Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBIL1TY MELANOMA-07
NL-OMON59923Phase 2Completed
- Sponsor
- Genmab
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of acasunlimab and pembrolizumab in cutaneous melanoma (CM) (2 arms), sponsored by Genmab. Primary endpoint: Objective response rate. Started Dec 2025; status: completed.
02
Drugs
acasunlimabpembrolizumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON59923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59923.